Icon of the Instituts for Quality and Efficiency in Health Care

Report

Dipyridamole and aspirin for secondary prevention after stroke or TIA

Status
Status: Commission completed
Project no.
A09-01
Last updated

Report documents

  1. Executive summary of the final report

    Dipyridamole and aspirin for secondary prevention after stroke or TIA

    published on
    Document type
    PDF document, 100 kB, EN, not accessible
    Download file : Executive summary of the final report (PDF document, 100 kB, EN, not accessible)

  2. Final report

    Dipyridamole and aspirin for secondary prevention after stroke or TIA

    published on
    Document type
    PDF document, 1 MB, DE, not accessible
    Download file : Final report (PDF document, 1 MB, DE, not accessible)

  3. Documentation and evaluation of comments on the preliminary report

    Dipyridamole and aspirin for secondary prevention after stroke or TIA

    published on
    Document type
    PDF document, 2 MB, DE, not accessible
    Download file : Documentation and evaluation of comments on the preliminary report (PDF document, 2 MB, DE, not accessible)

  4. Executive summary of the preliminary report

    Dipyridamole and aspirin for secondary prevention after stroke or TIA

    published on
    Document type
    PDF document, 60 kB, DE, not accessible
    Download file : Executive summary of the preliminary report (PDF document, 60 kB, DE, not accessible)

  5. Preliminary report

    Dipyridamole and aspirin for secondary prevention after stroke or TIA

    published on
    Document type
    PDF document, 1 MB, DE, not accessible
    Download file : Preliminary report (PDF document, 1 MB, DE, not accessible)

  6. Report plan version 1.0

    Dipyridamole and aspirin for secondary prevention after stroke or TIA

    published on
    Document type
    PDF document, 152 kB, DE, not accessible
    Download file : Report plan version 1.0 (PDF document, 152 kB, DE, not accessible)

  7. Documentation and appraisal of comments on the preliminary report plan

    Dipyridamole and aspirin for secondary prevention after stroke or TIA

    published on
    Document type
    PDF document, 621 kB, DE, not accessible
    Download file : Documentation and appraisal of comments on the preliminary report plan (PDF document, 621 kB, DE, not accessible)

  8. Preliminary report plan

    Dipyridamole and aspirin for secondary prevention after stroke or TIA

    published on
    Document type
    PDF document, 212 kB, DE, not accessible
    Download file : Preliminary report plan (PDF document, 212 kB, DE, not accessible)

Press releases

Ruxolitinib for myelofibrosis: indication of considerable added benefit

Advantages in symptoms and survival time in comparison with “best supportive care”
Press release

Treatment for stroke: dipyridamole plus ASA offers no advantages

Additional benefit versus ASA and clopidogrel is not proven / Major bleeding occurs more often with combination therapy
Press release

Additional information

IQWiG health information

The main symptoms of a stroke are paralysis and speech problems. The cause is usually a blocked blood vessel. A stroke is a medical emergency. It is very important to have a stroke treated quickly to prevent permanent damage. Rehabilitation helps to reduce the effects of a stroke.

Stroke

Project details

Project no.
A09-01
Commission
Commission awarded on 28.04.2011 by the Federal Joint Committee (GBA).
Report type
Report
Status
Commission completed
Department/Division
Drug Assessment
Topic
Heart and circulation

Contact

Press contact

+49 221 356850

press@iqwig.de

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form

Print page